« Previous | Next » | All Messages |  IAGX Message Board Home | recommend post |  Ignore Poster

IAGX News Imagenetix Reports Record Year; Sales Jump 66% -- Net Income Increases 62%, and Company Reports Nine Consecutive Quarters of Profits

For the fourth fiscal quarter ended March 31, 2005, the Company reported revenue of $2,614,142, a 59% increase compared to $1,645,199 reported for the same quarter for the prior fiscal year. For the fourth quarter, the Company reported net income of $56,213 compared to $239,841 reported for the same period last year.

For the year ended March 31, 2005, the Company reported revenue of $7,574,194, a 66% increase compared to $4,568,264 reported for the same period last year. For the fiscal year, the Company reported net income of $753,936, or $.08 per diluted share, a 62% increase compared to $465,043 or $.04 per diluted share, reported for the same period last year. For the fiscal year ending March 31, 2005, the Company incurred a tax rate of 26% compared to a tax rate of 15% for the fiscal year ending March 31, 2004.

Bill Spencer, President of Imagenetix, said, "I am pleased to report record sales and earnings for our fiscal year ending March 31, 2005. Sales have expanded as we have entered the mass market, and net income was positive in all four quarters of the year including the fourth quarter, a quarter in which heavy expenses were allocated to clinical costs, costs associated with a private equity raise, renewal of a spokesperson agreement, and an Imagenetix convention which hosted medical and scientific experts from North America."

"Since inception, we have successfully conducted over 20 scientific studies focused on our proprietary products and compounds regarding inflammation and inflammation related challenges," Mr. Spencer added. "With compelling and published scientific results, our products have received expanded news coverage on radio, television, and print, and have received over 150 media placements to date with an impression count of over 37,000,000 people."

Mr. Spencer went on to say, "Along with media coverage, mass market sales of Celadrin(R), our proprietary Imagenetix product that addresses a $22 billion market segment, began in the second half of the fiscal year. Celadrin(R) in oral format for joint function and mobility and Celadrin(R) in topical form for arthritis, aches and pains are now available in thousands of stores throughout the United States and Canada under various private labels. Stores carrying private labeled products which contain Celadrin(R) include Wal-Mart, GNC, Albertson's, Sav-On Drug, Longs Drug, The Vitamin Shoppe, Whole Foods, Wild Oats and others. This combination of media attention and mass market distribution, coupled with compelling products which are scientifically validated, has contributed to our record financial performance and should continue to bode well for our shareholders."

About Imagenetix

San Diego based Imagenetix, Inc. (OTCBB:IAGX), www.imagenetix.net, is focused on inflammation. With its patent pending compound, Imagenetix is focused on inflammatory diseases. With its natural based, proprietary products, the Company is focused on inflammation related markets. Imagenetix develops, formulates, private-labels, and produces nutritional supplements, over-the-counter topical creams, and skin care products to address these markets.

Mass market sales that address a $22 billion market segment, musculo-skeletal movement, have commenced for two of Imagenetix's proprietary products: Celadrin(R) oral for joint function and mobility, and Celadrin(R) topical for aches and pains.

Safe Harbor Statement

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company expects to file with the Securities Exchange Commission.